Synthetic Cannabinoids

RSS Feed for this category

Japan to Ban New Synthetic Drugs

The Japanese government will ban four new synthetic drugs in August, according to Japanese press reports. The four drugs are the synthetic cannabinoids JWH-018 and cannabicyclohexanol and the synthetic stimulants mephedrone and MDPV.

mephedrone among new synthetic drugs to be banned in Japan
The synthetic cannabinoids are commonly sold as incense and marketed in the US under brand names like Spice and K2. The synthetic stimulants are commonly sold as plant fertilizer and marketed under names such as Ivory Wave. The two types of synthetic drugs are commonly referred to as "fake pot" and "bath salts," respectively.

The compounds have been banned in the European Union, and numerous states in the US have also taken action to prohibit them. Legislation is pending in the US Congress to ban them as well, and both sets of drugs are currently banned federally under emergency DEA edicts.

The Japanese Health, Labor and Welfare Ministry will designate the four synthetic drugs as "narcotics" under the Pharmaceutical Affairs Law and is working on a blanket regulation that would allow it to impose the same designation on new drugs with slightly differing chemical compositions but that have similar effects to the banned substances.

Japanese health authorities have reported 114 cases of "health problems" associated with the use of the synthetic drugs, but there is no reporting on how many of those cases were associated with synthetic cannabinoids or how many were associated with synthetic stimulants. The adverse reactions to synthetic stimulants are more severe than those associated with synthetic cannabinoids. Authorities in Japan have also reported a number of cases of people injuring others while driving under the influence of the new synthetics.

Tokyo
Japan

US Senate Passes Synthetic Drug Ban, Without Mandatory Minimums [FEATURE]

The Senate has passed House Resolution 1254, the Synthetic Drug Control Act of 2011, which would federally criminalize the possession, distribution, and manufacture of synthetic cannabinoids ("fake marijuana") and synthetic stimulants ("bath salts"). The measure has already passed the House, and President Obama is expected to quickly sign it into law.

The synthetic cannabinoids are marketed as "herbal incense" and sold under brand names such as K2 and Spice, while the synthetic stimulants are marketed as "bath salts" and sold under a variety of names, including Ivory Wave and Vanilla Sky. Poison control centers and emergency rooms around the country have reported a sharp increase in synthetic drug incidents in the past two years, with Spice users reporting adverse effects similar to those sometimes reported with marijuana, while bath salts users have suffered more serious adverse effects, including hallucinations, psychotic breaks, and death.

Fake pot or bath salts or both are already banned in a number of states, and more states are considering criminalizing them. Both types of drugs have already been subject to emergency bans by the DEA while its legislatively mandated process for evaluating new drugs proceeds.

A widely publicized incident over the weekend in which a man chewed off parts of another man's face before being shot and killed by police has heightened concerns about the new synthetics, generating headlines like "Miami cannibal zombie-like attack linked to powerful 'bath salts' drug," but at this point, such claims are pure speculation. Police in the case have also posited "a new form of LSD" and "cocaine psychosis" to explain the attack, but any real information will have to await a toxicologist's report.

Sen. Rand Paul (R-KY) had single-handedly blocked passage of the bill for months by placing a senatorial hold on it. Paul objected to harsh mandatory minimum sentences in the bill, as well as to further broadening of the federal war on drugs.

But bill supporters, led by Sen. Charles Schumer (D-NY), resorted to a parliamentary maneuver to get it passed. They quietly attached it to an FDA regulatory bill, which the Senate passed last Wednesday.

Sen. Rand Paul got mandatory minimums removed
Still, Sen. Paul was able to insert language into the bill specifying that the Controlled Substance Act's mandatory minimum 20-year sentence for anyone supplying a drug that causes severe bodily harm or death to a user does not apply to the newly banned synthetics. That's because in order to get the FDA bill approved by Memorial Day, Sen. Rob Portman (R-OH), who actually sponsored the amendment adding the synthetics to the FDA bill, had to win unanimous consent for his amendment. Paul agreed not to object after Portman inserted the language about the mandatory minimums.

The bill still contains draconian sentencing provisions, including sentences of up to 20 years for a first sale or manufacturing offense and up to 30 years for a subsequent offense.

The bill's sponsors said after the vote that its passage would strike a strong blow against the new synthetics, but industry advocates and the Congressional Budget Office (CBO) disagree.

"Let this be a warning to those who make a profit manufacturing and selling killer chemical components to our teens and children: the jig is up," Schumer said in a statement. "This bill closes loopholes that have allowed manufacturers to circumvent local and state bans and ensures that you cannot simply cross state lines to find these deadly synthetic drugs."

"These new designer drugs can kill, and if we don't take action, they are going to become more and more prevalent and put more and more people at risk," Sen. Amy Klobuchar (D-MN), another sponsor of the bill said in a statement. "Today's action is good news for this critical legislation to give law enforcement the tools they need to crack down on synthetic drugs before they put more lives in danger, and I will continue to work to ensure these provisions are signed into law."

But the Retail Compliance Association (RCA), which represents smoke shop and convenience store operators and which opposed the bill, pointed out that the bill only bans five chemical families and only names 15 synthetic cannabinoids. Many of those compounds are already off the market, the RCA said, adding that the bill does not include hundreds of additional compounds unrelated to the chemical families banned under it.

"This bill will be touted as banning what law enforcement has deemed 'fake pot,' but it does no such thing; it actually only bans a few of the potential ingredients of these products, by no means the products themselves," said RCA spokesman Dan Francis. "The bill's range of enforcement may well be limited to the specifically named compounds because labs cannot test for chemical families, nor can the police or retailers. The products are tested by many different levels of this industry, and no lab I have spoken with has a test to determine the chemical family," Francis added.

The CBO, for its part, published a cost analysis of the bill in November that found its impact would be minimal.

"Based on information from industry and law enforcement experts, CBO expects that, by the date of the legislation's enactment, most vendors will have largely replaced the banned substances with new products because many states have already passed legislation banning some or all of the compounds listed in the bill and because the DEA has already issued emergency rules temporarily banning five cannabimimetic agents and three synthetic stimulants," the analysis found.

Still, Congress can pat itself on the back for "doing something" about the new synthetic drugs -- whether or not it actually does anything good.

Washington, DC
United States

Australia Bans Synthetic Marijuana

As of Tuesday, synthetic cannabis ("fake weed") products are illegal in Australia. The ban came when the Therapeutic Goods Administration placed eight groups of synthetic cannabinoids and all synthetic cannabinomimetics on the National Medical and Poisons Schedule.

"spice" or K2 packet (wikimedia.org)
Fake weed is already banned in at least 16 countries and an ever-growing number of US states. The DEA issued an emergency ban on the substances last year, but a bill to make that ban permanent has been stalled in Congress by a hold placed on it by Sen. Rand Paul (R-KY).

Fake weed consists of powdered synthetic cannabinoids, which are then sprayed on herbal matter and marketed under brand names including Kronic, K-2, and Spice. They produce a high similar to marijuana and sometimes create undesired side effects in users similar to those sometimes experienced with marijuana. No deaths in the US have been directly linked to their use.

Possession, manufacture, or sale of fake weed is now a criminal offense in Australia with violators facing fines or jail, including up to 10 years in prison for manufacturing and distribution offenses.

The ban came after police last month called for urgent meetings with public health and drug authorities. The state of Western Australia last year requested consideration of a national ban and had banned fake weed in its territory last year after a spate of highly-publicized hospitalizations of users, but no other Australian state had enacted a ban.

"These products do not appear to have any legitimate therapeutic use and there is a developing international body of evidence and clinical experience that is showing harm related to use of these substances," said Western Australia Mental Health Minister Helen Morton, who had championed the ban there last year. "Removing synthetic cannabinoids from legal supply, sale and possession is expected to result in a significant decrease in consumption and the associated harm related to their use," she told Perth Now.

Ironically, the surge in fake weed use in Western Australia came as the state government there toughened its marijuana laws last year. Prior to the enactment of that law last August, possession of up to 30 grams of pot had been decriminalized, but under the new law, those possessing more than 10 grams face up to two years in prison. The cultivation of up to two plants had also been decriminalized, but is now punishable by up to two years in prison as well.

Canberra
Australia

Warning: Sweaty, Disagreeable Teenagers Might Be High on Drugs

http://stopthedrugwar.org/files/spice.jpg

According to Dr. Sanjay Gupta at CNN, this synthetic marijuana stuff the kids are smoking these days is the worst thing to hit the scene since marijuana itself (gasp!), and parents had better add it to their list of things to be concerned about.

If you're a parent and suspect your child may be using synthetic marijuana, look for these signs: Excessive sweating, agitation, inability to speak, aggression and restlessness. If a teen is showing these symptoms, doctors recommend you seek medical attention for your child immediately. [CNN]

This is all very well-intended I'm sure, but it does occur to me that being high as all hell on dangerous synthetic drugs may not be the only possible explanation for why your teenager is sweaty, pissed-off, and not speaking to you.

For one thing, WebMD says these are symptoms of "Dementia in Head Injury," which is also a serious concern now that the Drug Czar is encouraging kids to do parkour instead of drugs. But before you call an ambulance and start racking up hospital bills, you might want to rule out the possibility that you're dealing with a perfectly normal hormonal adolescent who will cheer up in a year or two if you can manage not to panic and over-parent them until they snap.

In any case, some people are saying some really scary stuff about the risks of synthetic marijuana, and although I've been around it enough to doubt that its destructive potential lives up to the hype, I agree there's a lot we don't know. What we do know is that this stuff was invented for no other reason than to circumvent and cash in on the illegality of marijuana itself. No one would touch this crap – hell, it wouldn't even exist – but for the enormous, moronic war against the thing that people actually want when they're messing around with synthetic pot.

Whatever the story on this stuff turns out to be, there's only one perfect plan for making it go away and it rhymes with megalize larijuana.

Follow Scott Morgan on Twitter: www.twitter.com/drugblogger

DEA Extends Ban on Fake Marijuana Chemicals

The DEA has extended for another six months its emergency ban on five synthetic cannabinoids used to manufacture "fake weed" products. The chemicals are sprayed on herbal mixtures and the resulting product is sold under names including Spice and K2.

The agency first enacted the ban a year ago, but that emergency ban was set to expire last Thursday. The DEA published the extension in the federal register that same day.

The extension continues the ban on five synthetic cannabinoids: JWH-018, JWH-073, JWH-200, CP-47,497 (that's all one chemical CP-47,497) and cannabicyclohexanol. The ban means those substances are treated as Schedule I drugs under federal law.

"Schedule 1 substances are reserved for those substances with a high potential for abuse, no currently accepted medical use in treatment in the United States and a lack of accepted safety for use of the drug under medical supervision," the DEA reminded in a press release last Wednesday.

The American Association of Poison Control Centers reported last month that after synthetic marijuana products first appeared on their radar in 2009, generating several hundred calls, the number jumped to 2,906 calls in 2010 and 6,956 last year. Their data also showed that the number of calls peaked in July 2011 at 705 and have declined since then, with 551 calls reported in December.

The poison centers and emergency room doctors have reported such symptoms as disorientation, elevated heart rates, and vomiting, similar to those reported from adverse reactions to marijuana. There are no confirmed reports of overdose deaths, and only a handful of deaths potentially linked to synthetic marijuana, including a trio of suicides after use, a young man killed in a traffic accident while driving after use, and a 13-year-old Pennsylvania boy who smoked synthetic weed out of a plastic Pez dispenser and later died of complications from a lung transplant.

"We continue to address the problems of synthetic drug manufacturing, trafficking, and abuse. Our efforts have clearly shown that these chemicals present an imminent threat to public safety," said DEA Administrator Michele M. Leonhart. "This six month extension is critical and gives us the time necessary to conduct the administrative scheduling process for permanent control.

A number of states have and localities have already banned synthetic marijuana, and more are moving to do so this year. Federal legislation that would ban both synthetic marijuana and new synthetic stimulants ("bath salts") has passed the House, but is being blocked in the Senate by a hold placed on it by Sen. Rand Paul (R-KY).

This week, the Drug Policy Alliance (DPA) joined the American Civil Liberties Union, NAACP and nearly 40 other organizations on a letter to members of the Senate urging them to oppose the legislation. In a separate press release, DPA urged Congress to not just reject the synthetic drug legislation but also overhaul US drug policy, pointing out that last year marked the 40th Anniversary of President Nixon declaring a war on drugs, and despite the government arresting tens of millions of nonviolent Americans and spending more than a trillion dollars, drugs are cheap, potent, and readily available in every community.

"Senator Rand Paul is standing up to both political parties and doing what it takes to protect Kentucky taxpayers from the career politicians in Washington who want to waste more money on failed drug policies," said Bill Piper, DPA director of national affairs. "He should be applauded for opposing government waste and supporting public safety. The failed war on drugs costs too much and achieves too little; it is time for a new approach."

Washington, DC
United States

Rand Paul Blocks Federal Synthetic Drug Bans

Sen. Rand Paul (R-KY) is blocking three Senate bills that seek to prohibit new synthetic drugs. Rand spokesperson Moira Bagley confirmed to the Lexington Herald-Leader that he has had a "hold" on the bills for the last three months and that he has no intention of lifting it.

Rand Paul
Under Senate "unanimous consent" rules, any senator can place a hold on any bill. A hold doesn't kill a bill, but makes it more difficult for it to pass. A bill with a senatorial hold would require 60 votes to bring it up for consideration over the holding senator's objection.

Paul's main reason for blocking the bills, he told the Kentucky New Era, is that federal penalties for drug law violations are "disproportionate" and doesn't allow judges discretion in sentencing. "The main reason we are opposing this is someone could be kept in prison for 20 years," he told the Era.

Another reason Paul blocked the bills is that he believes "enforcement of most drug laws can and should be local and state issues" and that the bans could hinder efforts to be beneficial research on the substances, Bagley told the Herald-Leader. Bagley added that the federal government has the authority to issue "emergency" bans of the synthetic drugs without needing congressional action. (The DEA has in fact enacted separate temporary bans on synthetic cannabinoids and synthetic stimulants.)

The substances in question are synthetic cannabinoids ("fake weed") sold under names such as Spice and K2, as well as synthetic stimulants being sold as "bath salts." The substances have become increasingly widespread since being introduced here in recent years, but so have reports of adverse reactions and emergency room visits linked to them.

The bills in question are Senate Bill 409, introduced by inveterate drug warrior Sen. Chuck Schumer (D-NY); Senate Bill 605, introduced by inveterate drug warrior Sen. Charles Grassley (R-IA), and Senate Bill 389, introduced by Sen. Amy Klobuchar (D-MN).

A similar, but not identical, measure, House Bill 1254, passed the House in December. If any of the Senate bills manage to get passed, they would have to be reconciled with the House bill in conference committee.

But prospects for their passage are complicated at best, given the 60-vote firewall, and the fact that the Senate has other pressing business to attend to. That has the bills' sponsors frustrated. Last week, they took the unusual step of taking to the Senate floor to urge Paul to lift his hold.

Schumer said that while he understood the right of a senator to block a bill, Paul shouldn't be able to block a debate. "Let's see if he can win people over to his point of view," he said.

"Let's hear what the objections are, and then pass these bills," said Klobuchar.

But it doesn't look like Paul is budging.

Washington, DC
United States

The Top Ten Domestic US Drug Policy Stories of 2011 [FEATURE]

http://stopthedrugwar.org/files/usmap-small.jpg
We can put 2011 to bed now, but not before looking back one last time at the good, the bad, and the ugly. It was a year of rising hopes and crushing defeats, of gaining incremental victories and fending off old, failed policies. And it was a year in which the collapse of the prohibitionist consensus grew ever more pronounced. Let's look at some of the big stories:

Progress on Marijuana Legalization

Last year saw considerable progress in the fight for marijuana legalization, beginning in January, when Law Enforcement Against Prohibition (LEAP) got President Obama to say that legalization (in general) is "an entirely legitimate topic for debate," and that while he does not favor it, he does believe in "a public health-oriented approach" to illicit drugs. Before the LEAP intervention, which was made via a YouTube contest, legalization was "not in the president's vocabulary." While we're glad the president learned a new word, we would be more impressed if his actions matched his words. Later in the year, in response to "We the People" internet petitions, the Obama White House clarified that, yes, it still opposes marijuana legalization.

In June, Reps. Barney Frank (D-MA) and Ron Paul (R-TX) made history by introducing the first ever bill in Congress to end federal marijuana prohibition, H.R. 2306. It hasn't been scheduled for a hearing or otherwise advanced in the legislative process, but it has garnered 20 cosponsors so far. Sadly, its lead sponsors are both retiring after this term.

Throughout the year, there were indications that marijuana legalization is on the cusp of winning majority support among the electorate. An August Angus Reid poll had support at 55%, while an October Gallup poll had it at 50%, the first time support legalization has gone that high since Gallup started polling the issue. A November CBS News poll was the downside outlier, showing support at only 40%, down slightly from earlier CBS polls. But both the Angus Reid and the Gallup polls disagreed with CBS, showing support for legalization trending steadily upward in recent years.

Legalization is also polling reasonably -- if not comfortably -- well in Colorado and Washington, the two states almost certain to vote on initiatives in November. In December, Public Policy Polling had legalization leading 49% to 40% in Colorado, but that was down slightly from an August poll by the same group that had legalization leading 51% to 38%.

In Washington, a similar situation prevails. A January KING5/SurveyUSA poll had 56% saying legalization would be a good idea and 54% saying they supported marijuana being sold at state-run liquor stores (similar to what the I-502 initiative proposes), while a July Elway poll had 54% either definitely supporting legalization or inclined to support it. But by September, the Strategies 360 Washington Voter Survey had public opinion evenly split, with 46% supporting pot legalization and 46% opposed.

The polling numbers in Colorado and Washington demonstrate that victory at the polls in November is in reach, but that it will be a tough fight and is by no means a sure thing. "Stoners Against Proposition 19"-style opposition in both states isn't going to help matters, either.

Oh, and Connecticut became the 14th decriminalization state.

Medical Marijuana Advances…

In May, Delaware became the 16th state to enact a medical marijuana law. Under the law, patients with qualifying conditions can legally possess up to six ounces of marijuana, but they cannot grow their own. Instead, they must purchase it from a state-licensed compassion center. That law will go into effect this year.

Meanwhile, New Jersey and Washington, DC, continue their achingly slow progress toward actually implementing existing medical marijuana laws. In New Jersey, Gov. Chris Christie (R) finally got out of the way and okayed plans for up to six dispensaries, but early efforts to set them up are running into NIMBY-style opposition. In DC, a medical marijuana program approved by voters in 1998 (!) but thwarted by Congress until 2009 is nearly at the stage of selecting dispensary operators. One of these months or years, patients in New Jersey and DC may actually get their medicine.

And late in the year, after the federal government rejected a nine-year-old petition seeking to reschedule marijuana, the governors of Rhode Island, Vermont, and Washington formally asked the Obama administration to reschedule it so that states could regulate its medical use without fear of federal interference. As the year came to an end, Colorado joined in the request for rescheduling.

…But the Empire Strikes Back

Last year saw the Obama administration recalibrate its posture toward medical marijuana, and not for the better. Throughout the year, US Attorneys across the country sent ominous signals that states attempting to regulate medical marijuana dispensaries could face problems, including letters to state governors not quite stating that state employees involved in regulation of the medical marijuana industry could face prosecution. That intimidated public officials who were willing to be intimidated, leading, for example, to New Jersey Gov. Chris Christie (R) delaying his state's medical marijuana program, Rhode Island Gov. Lincoln Chafee (I) to kill plans for dispensaries there, and Washington Gov. Christine Gregoire (D) to veto key parts of a bill there that would have regulated dispensaries.

Then the feds hit hard at Montana, raiding dispensaries and growers there, even as the state law was under attack by conservative Republican legislators. Now, Montana medical marijuana providers are heading to federal prison, and the state law has been restricted. What was once a booming industry in Montana has been significantly stifled.

There have also been raids directed at providers in Colorado, Michigan, Oregon, and Washington, but California has been the primary target of federal attention in the latter half of the year. Since a joint offensive by federal prosecutors in the state got underway in October, with threat letters being sent to numerous dispensaries and their landlords, a great chill has settled over the land. Dispensary numbers are dropping by the day, the number of lost jobs number in the thousands, and the amount of tax revenues lost to local jurisdictions and the state is in the millions. That's not to mention the patients who are losing safe access to their medicine.

It's unclear whether the impetus for the crackdown originated in the Dept. of Justice headquarters in Washington or with individual US Attorneys in the states. Advocates hope it will stay limited mainly to states that are not effectively regulating the industry, and a coalition in California has filed a ballot initiative for 2012 that would do just that. Either way there is plenty of pain ahead, for patients and for providers who took the president's and attorney general's earlier words on the subject at face value.

Synthetic Panic

Last year, Congress and state and local governments across the land set their sights on new synthetic drugs, especially synthetic cannabinoids ("fake marijuana") and a number of methcathinone derivatives ("bath salts") marketed for their stimulating effects similar to amphetamines or cocaine. Confronted with these new substances, politicians resorted to reflex prohibitionism, banning them as fast as they could.

Some 40 states and countless cities and counties have imposed bans on fake weed or bath salts or both, most of them acting this year.

At the federal level, the DEA enacted emergency bans on fake weed -- after first being temporarily blocked by retailers -- and then bath salts until Congress could act. It did so at the end of the year, passing the Synthetic Drug Control Act of 2011. The bill makes both sets of substances Schedule I drugs under the Controlled Substances Act, which will pose substantial impediments to researching them. Under the bill, prison sentences of up to 20 years could be imposed for the distribution of even small quantities of the new synthetics.

But the prohibitionists have a problem: Synthetic drug makers are responding to the bans by bringing new, slightly different formulations of their products to market. Prosecutors are finding their cases evaporating when the find the drugs seized are not the ones already criminalized, and retailers are eager to continue to profit from the sales of the new drugs. As always, the drug law enforcers are playing catch-up and the new drug-producing chemists are way ahead of them.

The Drug War on Autopilot: Arrests Hold Steady, But Prisoners Decline Slightly

overcrowded Mule Creek State Prison, CA
Last year saw more evidence that drug law enforcement has hit a plateau, as 2010 drug arrests held steady, but the number of prisoners and people under correctional supervision declined slightly.

More than 1.6 million people were arrested for drug offenses in the US in 2010, according to the FBI's Uniform Crime Report 2010, and more than half of them were for marijuana. That's a drug arrest every 19 seconds, 24 hours a day, every day last year. The numbers suggest that despite "no more war on drugs" rhetoric emanating from Washington, the drug war juggernaut is rolling along on cruise control.

Overall, 1,638,846 were arrested on drug charges in 2010, up very slightly from the 1,633,582 arrested in 2009. But while the number of drug arrests appears to be stabilizing, they are stabilizing at historically high levels. Overall drug arrests are up 8.3% from a decade ago.

Marijuana arrests last year stood at 853,838, down very slightly from 2009's 858,408. But for the second year in a row, pot busts accounted for more arrests than  all other drugs combined, constituting 52% of all drug arrests in 2010. Nearly eight million people have been arrested on pot charges since 2000.

The vast majority (88%) off marijuana arrests were for simple possession, with more than three-quarters of a million (750,591) busted in small-time arrests. Another 103,247 people were charged with sale or manufacture, a category that includes everything from massive marijuana smuggling operations to persons growing a single plant in their bedroom closets.

An analysis of the Uniform Crime Report data by the University of Maryland's Center for Substance Abuse Research added further substance to the notion that drug enforcement is flattening. The center found that the arrest rate for drug violations has decreased for the last four years, but still remains more than twice as high as rates in the early 1980s. The all-time peak was in 2006.

Meanwhile, the Bureau of Justice Statistics reported that for the first time since 1972, the US prison population in 2010 had fallen from the previous year and that for the second year in a row, the number of people under the supervision of adult correctional authorities had also declined.

In its report Prisoners in 2010, BJS reported that the overall US prison population at the end of 2010 was 1,605,127, a decrease of 9,228 prisoners or 0.6% from year end 2009. The number of state prisoners declined by 0.8% (10,881 prisoners), while the number of federal prisoners increased by 0.8% (1.653 prisoners). Drug offenders accounted for 18% of state prison populations in 2009, the last year for which that data is available. That's down from 22% in 2001. Violent offenders made up 53% of the state prison population, property offenders accounted for 19%, and public order or other offenders accounted for 9%.

In the federal prison population, drug offenders made up a whopping 51% of all prisoners, with public order offenders (mainly weapons and immigration violations) accounting for an additional 35%. Only about 10% of federal prisoners were doing time for violent offenses. Overall, somewhere between 350,000 and 400,000 people were doing prison time for drug offenses last year.

Similarly, in its report Correctional Population in the US 2010, BJS reported that the number of people under adult correctional supervision declined 1.3% last year, the second consecutive year of declines. The last two years are the only years to see this figure decline since 1980.

At the end of 2010, about 7.1 million people, or one in 33 adults, were either in prison or on probation or parole. About 1.4 million were in state prisons, 200,000 in federal prison, and 700,000 in jail, for a total imprisoned population of about 2.3 million. Nearly 4.9 million people were on probation or parole.

America's experiment with mass incarceration may have peaked, exhausted by its huge costs, but change is coming very slowly, and we are still the world's unchallenged leader in imprisoning our own citizens.

Federal Crack Prisoners Start Coming Home

Hundreds of federal crack cocaine prisoners began walking out prison in November, the first beneficiaries of a US Sentencing Commission decision to apply retroactive sentencing reductions to people already serving time on federal crack charges. As many as 1,800 federal crack prisoners were eligible for immediate release and up to 12,000 crack prisoners will be eligible for sentence reductions that will shorten their stays behind bars.

The releases come after Congress passed the Fair Sentencing Act in August 2010, which shrank the much criticized disparity between mandatory minimum sentences for crack and powder cocaine from 100:1 to 18:1. After Congress acted, the Sentencing Commission then moved to make those changes retroactive, resulting in the early releases beginning in November.

Despite the joyous reunions taking place across the country, the drug war juggernaut keeps on rolling, and there is much work remaining to be done. Not all prisoners who are eligible for sentence reductions are guaranteed to receive one, and retroactivity won't do anything to help people still beneath their mandatory minimum sentences. A bill with bipartisan support in Congress, H.R. 2316, the Fair Sentencing Clarification Act, would make Fair Sentencing Act changes to mandatory minimum sentences retroactive as well, so that crack offenders left behind by the act as is would gain its benefits.

And the Fair Sentencing Act itself, while an absolute advance from the 100:1 disparity embodied in the crack laws, still retains a scientifically unsupportable 18:1 disparity. For justice to obtain, legislation needs to advance that treats cocaine as cocaine, no matter the form it takes.

But even those sorts of reforms are reforms at the back end, after someone has already been investigated, arrested, prosecuted, and sentenced. Radical reform that will cut the air supply to the drug war incarceration complex requires changes on the front end.

Also in November, the US Supreme Court announced that it will decide whether the Fair Sentencing Act should be applied to those who were convicted, but not sentenced, before it came into effect -- the so-called "pipeline" cases. The decision to take up the issue came after lower courts split on the issue. The Supreme Court is expected to rule on the issue in June.

Drug Testing the Needy

drug testing lab
With state budgets strained by years of recession and slow recovery, lawmakers across the country are turning their sights on the poor and the needy. In at least 12 states, bills have been introduced that would require people seeking welfare or unemployment benefits to undergo drug testing and risk losing those benefits if they test positive. Some Republicans in the US Congress want to do the same thing. In a thirteenth state, Michigan, the state health department is leading the charge.

The race to drug test the needy appears to be based largely on anecdotal and apocryphal evidence. South Carolina Gov. Nikki Hailey (R), to take one example, cited reports that a nuclear installation there couldn't fill vacancies because half the applicants failed drug tests, but had to retract that statement because it was nowhere near to being true. In Florida, where welfare drug testing was briefly underway before being halted by a legal challenge, 96% of applicants passed drug tests, while in an Indiana unemployment drug testing program, only 2% failed.

While such legislation appeals to conservative values, it is having a tough time getting passed in most places, partly because of fears that such laws will be found unconstitutional. The federal courts have historically been reluctant to approve involuntary drug testing, allowing it only for certain law enforcement or public safety-related occupations and for some high school students. When Michigan tried to implement a welfare drug testing program more than a decade ago, a federal appeals court ruled that such a program violated welfare recipients' right to be free from unreasonable searches and seizures.

That ruling has served to restrain many lawmakers, but not Florida Gov. Rick Scott (R) and the Florida legislature. Scott issued an executive order to drug test state employees, but had to put that on hold in the face of threatened legal challenges. The state legislature passed and Scott signed a bill requiring welfare applicants and recipients to undergo drug testing or lose their benefits.

But the ACLU of Florida and the Florida Justice Institute filed suit in federal court to block that law on the grounds it violated the Fourth Amendment. In October, a federal judge granted a preliminary injunction preventing the state from implementing it. A final decision from that court and decisions about whether it will be appealed are eagerly awaited.

Marking 40 Years of Failed Drug War

Drug War 40th anniversary demo, San Francisco
June 17 marked forty years since President Richard Nixon, citing drug abuse as "public enemy No. 1," declared a "war on drugs." A trillion dollars and millions of ruined lives later, a political consensus is emerging that the war on drugs is a counterproductive failure. The Drug Policy Alliance led advocates all across the country in marking the auspicious date with a day of action to raise awareness about the catastrophic failure of drug prohibition and to call for an exit strategy from the failed war on drugs. More than 50 events on the anniversary generated hundreds of local and national stories.

In dozens of cities across the land, activists, drug war victims, and just plain folks gathered to commemorate the day of infamy and call for an end to that failed policy. Messages varied from city to city -- in California, demonstrators focused on prison spending during the budget crisis; in New Orleans, the emphasis was on racial injustice and harsh sentencing -- but the central overarching theme of the day, "No More Drug War!" was heard from sea to shining sea and all the way to Hawaii.

The crowds didn't compare to those who gather for massive marijuana legalization protests and festivals -- or protestivals -- such as the Seattle Hempfest, the Freedom Rally on Boston Commons, or the Ann Arbor Hash Bash, or even the crowds that gather for straightforward pot protests, such as 420 Day or the Global Marijuana March, but that's because the issues are tougher. People have to break a bit more profoundly with drug war orthodoxy to embrace completely ending the war on drugs than they do to support "soft" marijuana. That relatively small groups did so in cities across the land is just the beginning.

Congress Reinstates the Federal Ban on Funding Needle Exchanges

Two years ago, after years of advocacy by public health and harm reduction advocates, the longstanding ban on federal funding for needle exchanges was repealed. Last month, the ban was restored as the Senate took the final votes to approve the 2012 federal omnibus spending bill.

It was a Democratic-controlled House and Senate that rescinded the ban two years ago, and it was House Republicans who were responsible for reinstating it this year. Three separate appropriations bills contained language banning the use of federal funds, and House negotiators managed to get two of them into the omnibus bill passed Saturday.

A Labor-Health and Human Services appropriations bill including the ban on domestic use of federal funds for needle exchanges and a State Department bill including a ban on funding for needle exchange access in international programs both made it into the omnibus bill.

The Centers for Disease Control and Prevention (CDC), American Medical Association, National Academy of Sciences, American Public Health Association, and numerous other scientific bodies have found that syringe exchange programs are highly effective at preventing the spread of HIV/AIDS and other infectious diseases. Eight federal reports have found that increasing access to sterile syringes saves lives without increasing drug use.

Needle exchange supporters said restoring the ban will result in thousands of Americans contracting HIV/AIDS, hepatitis C or other infectious diseases next year alone.

US Drug War Deaths

As far as we know, nobody has ever tried to count the number of people killed in the US because of the war on drugs. We took a crack at it last year, counting only those deaths directly attributable to drug law enforcement activities. The toll was 54, including three law enforcement officers.

Most of those killed were shot by police, many of them while in possession of firearms (some in their own homes) and some of them while shooting at police. Some were shot in vehicles after police said they tried to run them down (why is it they never were merely trying to get away?). But not all died at the hands of police -- several died of drug overdoses from eating drugs while trying to evade arrest, several more died from choking on bags of drugs they swallowed, one man drowned after jumping into a river to avoid a pot bust, and another died after stepping in front of a speeding semi-trailer while being busted for meth.

People were killed in "routine traffic stops," SWAT-style raids, and undercover operations. Hardly any of those cases made more than a blip in local media, the two exceptions being the case of Jose Guerena, an Iraq war vet gunned down by an Arizona SWAT team as he responded to his wife's cry of intruders in his own home, and the case of Eurie Stamps Sr., a 68-year-old Massachusetts man accidentally shot and killed by a SWAT team member executing a warrant for small-time crack sales.

Our criteria were highly restrictive and absolutely undercount the number of people who are killed by our drug laws. They don't include, for instance, people who overdosed unnecessarily because they didn't know what they were taking or medical marijuana patients who die after being refused organ transplants. Nor do they include cases where people embittered by the drug laws go out in a blaze of glory that wasn't directly drug law-related or cases, like the four men killed last year by Miami SWAT officers during an undercover operation directed at drug house robbers.

The toll of 54 dead, then, is an absolute minimum figure, but it's a start. We will keep track again this year, and look for a report on last year's numbers in the coming weeks.

In Conclusion...

Last year had its ups and downs, its victories and defeats, but leaves drug reformers and their allies better placed than ever before to whack away at drug prohibition. This year, it looks like voters in Colorado and Washington will have a chance to legalize marijuana, and who know what else the new year will bring. At the least, we can look forward to the continuing erosion of last century's prohibitionist consensus.


 

US House Votes to Ban New Synthetic Drugs

The House of Representatives voted last Thursday to pass HR 1254, the Synthetic Drug Control Act of 2011, which would criminalize not only synthetic stimulants ("bath salts"), but also synthetic cannabinoids ("fake pot") marketed under names such as "K2" and "Spice."

Spice and other synthetic cannabinoids and stimulants will be banned under the bill passed by the House (wikimedia.org)
The bill passed on a roll call vote of 317-98. Sixteen Republicans joined with 82 Democrats to vote against the prohibitionist measure.

At least 40 states have passed bans on the new synthetic drugs, and the DEA has placed both fake pot and bath salts under emergency bans. The bill would make both sets of substances Schedule I drugs under the Controlled Substances Act, which would pose substantial impediments to researching them. Scientists have warned Congress that placing the synthetic drugs under Schedule I will have a chilling effect on ongoing efforts to explore treatments for a range of diseases and disorders.

Under the bill, prison sentences of up to 20 years could be imposed for the distribution of even small quantities of the new synthetics.

Seeking some small solace in the wake of the vote, Bill Piper, national affairs director for the Drug Policy Alliance, which had lobbied to defeat the bill, said it was "significant" that nearly a hundred members of the House had broken with drug war orthodoxy to vote against the bill.

Washington, DC
United States

US House Set to Pass Bad Drug Bills [FEATURE]

Going in the face of an ever-increasing clamor to reform decades of failed drug policies, the US House of Representatives is poised to pass two bills that promise more of the same. The House is set to vote any day now -- the vote was originally set until Wednesday night, but was pushed back -- on HR 1254, the Synthetic Drug Control Act of 2011, which would criminalize not only synthetic stimulants ("bath salts"), but also synthetic cannabinoids ("fake pot") marketed under names such as "K2" and "Spice."

"This is almost certain to pass," said Grant Smith, federal affairs coordinator for the Drug Policy Alliance (DPA), which has been lobbying to try to stop it. "We're doing our best to try to block it, but it's unlikely we will succeed," he said.

The bill foresees prison sentences of up to 20 years for the distribution of small quantities of synthetic drugs. But despite an intense debate in the House Judiciary Committee last month over the bill's implications, it is moving ahead.

At least 40 states have passed bans on the new synthetic drugs, and the DEA has placed both fake weed and bath salts under emergency bans. The bill would make both sets of substances Schedule I drugs under the Controlled Substances Act, which would make them difficult to research. Scientists have warned Congress that placing synthetic drugs under Schedule I will have a chilling effect on research intended to explore treatments for a range of diseases and disorders.

The bath salts drugs -- primarily methcathinones like mephedrone derived from the khat plant -- have been associated with spectacular bad reactions, including increased blood pressure, increased heart rate, agitation, hallucinations, extreme paranoia and delusions, and some reports of violent behavior. Fake pot has been associated with less dangerous bad reactions, including confusion, nausea and panic attacks.

The American Association of Poison Control Centers warned in May that it had seen a nine-fold increase in bath salts-related calls over the previous year, and that was with less than half the year gone. Last year, centers reported 302 calls; as of May of this year, they had received more than 2,200 calls.

That would clearly seem to suggest that use of bath salts is on the rise, but what it means beyond that is not so clear. Without a handle on actual use levels, it is difficult to determine how frequent such adverse reactions are, or how they compare to reported adverse events with other drugs.

Still, Mark Ryan, director of the Louisiana Poison Center, said the substances are the worst he has seen in 20 years at the poison center. "These products create a very severe paranoia that we believe could cause users to harm themselves or others," he said.

Horrible drugs or not, evidence from Britain suggests that some people like them quite a bit. According to an August report in the Guardian, which cited recently released scientific research, "Mephedrone is more popular among UK clubbers than ecstasy despite being banned."

"The legal status wasn't considered important," said Fiona Measham, a criminology lecturer who led the research. "Among the people we spoke to, I was surprised how much they liked it, how much they enjoyed it. They wanted to take more and were prepared to seek it out and buy it on the illegal market."

But Congress was on a different wavelength. In a statement typical of congressional discourse on the issue, in a September hearing, Rep. Charles Dent (R-PA), the sponsor of HB 1254, first listed a number of anecdotal scare stories, then proceeded to warn his colleagues that the drugs were not innocent. "These substances are marketed with innocent sounding names," he said, "but these labels are total misnomers designed to facilitate their legal sale. These drugs have no legitimate medicinal or industrial purposes."

"We are in a new era of drugs," said Sen. Diane Feinstein (D-CA) at the same time, as she prepared to deal with them with the same approach Congress has taken with other drugs -- by banning them.

The second bill, HR 313, the Drug Trafficker Safe Harbor Elimination Act of 2011, introduced by veteran drug warrior Rep. Lamar Smith (R-TX) would make it a criminal offense to plan to engage in an activity in another country if that activity would violate US drug laws if committed in the US -- even if that activity is legal in the country where it takes place.

While Smith and other bill supporters say the legislation is aimed at drug traffickers who conspire in the US, opponents point out that it could just as easily be applied to someone who makes plans to attend and partake at the Cannabis Cup in Amsterdam, work at a safe injection site in Vancouver or any of the other 64 cities that have them, or work in a medical marijuana program in Israel. All of those activities are illegal under federal drug laws and thus subject to the purview of the bill.

"Since the war on drugs was declared 40 years ago, the US has spent more than one trillion dollars and arrested tens of millions of Americans for drug law violations, yet drugs are readily available in every community and the problems associated with them continue to mount," said Bill Piper, DPA director of national affairs. "When you're in a hole, you shouldn't just keep digging," he added.

"Facing massive budget deficits, policymakers from both parties should be searching for alternatives to prison for nonviolent drug law offenders, because locking them up is only making us poorer, not safer," said Piper. "The US can't incarcerate its way out of its drug problems and should stop trying. The only way out of the drug war mess is to start treating drug use as a health issue instead of a criminal justice issue."

"By rushing to criminalize synthetic drugs, Congress is condemning more Americans to years in prison and ignoring warnings from the scientific community that this bill will hurt medical research," said Smith. "Outright criminalization compromises both public health and safety by shifting demand for synthetic drugs into the criminal market. It would be more effective for Congress to pursue comprehensive drug education and create a regulatory framework to reduce youth access to synthetic drugs. This approach is working for tobacco, which has contributed to more deaths than alcohol and illicit drugs combined."

Washington, DC
United States

Drug Policy Prospects on Capitol Hill This Year [FEATURE]

There are nearly two dozen pieces of drug policy-related legislation pending on Capitol Hill, but given a bitterly divided Congress intently focused on the economic crisis and bipartisan warfare in the run-up to the 2012 election, analysts and activists are glum about the prospects for passing reform bills and even gloomier about the prospects for blocking new prohibitionist bills.

uphill climb for reform this year
But while drug reform in the remainder of the 112th Congress may take on the aspect of slow-moving trench warfare, there is work to be done and progress to be made, advocates interviewed by Drug War Chronicle said. And intensely expressed congressional concern over federal budget deficits could provide opportunities to take aim at the federal drug war gravy train.

Bills to reform drug policy or of relevance to drug policy reform this session run the gamut from hemp legalization, medical marijuana reforms, and marijuana legalization to various sentencing reform and ex-offender re-entry measures, as well as a pair of bills aimed at protecting public housing residents from eviction because a family member commits a drug offense. Also worth mentioning is Sen. Jim Webb's (D-VA) National Criminal Justice Commission Act of 2011, which, if it were to pass, would be a feather in the soon-to-be-retiring senator's cap.

On the other side of the issue, the most intense prohibitionist fervor this session is centered around banning new synthetic drugs, with five bills introduced so far to criminalize the possession and trade in either synthetic cannabinoids ("fake weed"), or synthetic stimulants ("bath salts"), or both. Other regressive bills would ban anyone with a drug arrest from owning a gun and require states to drug test welfare recipients. A hearing on welfare drug testing is reportedly coming soon. Conservative Republican-controlled House foreign affairs and national security committees could also see efforts to boost drug war spending in Mexico or other hard-line measures in the name of fighting the cartels.

[To see all the drug policy-related bills introduced so far in Congress, as well as legislation introduced in the states, visit our new Legislative Center.]

While advocates are ready to do battle, the political reality of a deeply divided Congress in the run-up to a presidential election in the midst of deep economic problems means drug policy is not only low on the agenda, but also faces the same Republican House/Democratic Senate gridlock as any other legislation.

"The inertia is not exclusive to sentencing or drug policy reform," said Kara Gotsch of the Sentencing Project. "Nothing is moving. There is such a deadlock between the House and the Senate and the Republicans and the Democrats in both chambers. I don't think failure to move in this Congress is necessarily a sign of limited interest in reform, but the political fighting means nothing moves."

"The House is passing stuff with no expectation it will pass the Senate," said Eric Sterling, executive director of the Criminal Justice Policy Foundation. "The whole Congress right now is in a state of suspended animation, waiting to see whether Obama is reelected or not and whether the Senate goes Republican or not. The gridlock we all see in the headlines around big issues such as taxes and spending filters down to almost every committee and every issue."

And with Republicans in control of the House, the prospects for marijuana law reform in particular are grim in the short term, the former House Judiciary Committee counsel said. "I don't think there is going to be any positive legislative action," Sterling predicted. "The House is not going to take up the medical marijuana bills and it's not going to take up the Frank-Paul legalization bill. They won't even get hearings."

"I don't think any of these marijuana bills will pass with this Congress, but they're very important as placeholders," agreed Morgan Fox, communications director for the Marijuana Policy Project. "As long as those bills are out there, we can keep bringing the issue in front of lawmakers and continue to educate them about this."

Even stalled bills provide opportunities for advancement, Sterling concurred. "That's not to say there isn't important education that can be done, and organizing and encouraging members to cosponsor good legislation. They need to be educated. The test of whether the effort is worthwhile or not is whether it can be passed this session," he offered. "The political stars are not lined up.

Jim Webb at 2007 hearing on incarceration (photo from sentencingproject.org)
Medical marijuana legislation in Congress includes a pair of bills aimed at making the financial system friendlier to dispensaries and other medical marijuana-related businesses, as well as a bill that would reschedule marijuana for prescription use:

  • Introduced by Rep. Jared Polis (D-CO), H.R. 1984, the Small Business Banking Improvement Act of 2011, would protect financial institutions that accept medical marijuana deposits from federal fines or seizures and having to file "suspicious activity" reports. Such threats have prompted major banks to stop doing business with dispensaries.
  • Introduced by Rep. Pete Stark (D-CA), H.R. 1985, the Small Business Tax Equity Act of 2011, would allow dispensaries to deduct expenses like any other business and is designed to avoid unnecessary IRS audits of dispensaries and put an end to a wave of audits already underway.
  • The marijuana rescheduling bill, H.R. 1983, the States' Medical Marijuana Patient Protection Act, would also specifically exempt from federal prosecution people in compliance with state medical marijuana laws. It was introduced by Rep. Barney Frank (D-MA).

"We're having our grassroots support all three pieces of legislation, but our primary thrust is H.R. 1983," said Kris Hermes, spokesman for Americans for Safe Access. "It's tough to get people engaged at the federal level, but we've mounted a social media campaign and want to promote the bill through Facebook and other methods, getting some viral participation in something that should be important for most patients around the country."

Part of the group's difficulty in getting members to focus on Congress is because they are busy fending off assaults at the state and local level, said Hermes. "We've had many instances of state officials doing an about-face on implementation of state laws or further restricting them, so the battleground has become very focused and localized," he noted.

"That takes energy away from what's going on at the federal level, and that's the real tragedy because it's the federal government that's at the root of all the opposition and tension taking place at the local level," Hermes said, pointing to this year's spate of threatening letter from US Attorneys to elected officials. "Having to fight this locally takes energy away from what's going on at the federal level."

Aaron Smith of the National Cannabis Industry Association, the recently formed trade association for marijuana businesses, said his group was focused on the financial bills. "I'm not holding my breath on the Republicans in the House, but the very introduction of these bills is progress," he said. "For the first time, we're actually seeing some of the industry's issues addressed. We think we'll see more traction for these bills than the broader legalization issue. There's already an industry clamoring for regulation, and federal laws are getting in between states and businesses in those states. We will be seeing state officials supporting these reforms. It's hard to write a check to the IRS or state treasuries when you can't have a banking account."

While the association is not predicting passage of the bills this session, it will be working toward that goal, Smith said. "We can get more cosponsors and we will be working to raise awareness of the issue," he said. "Just a year ago, no one even knew about these problems, now they are being addressed, and that's progress in itself."

But Congress is not the only potential source of relief for the industry, Smith said. "It would be helpful if we could get a memo from the Department of the Treasury clarifying that businesses licensed under their respective state laws are not a banking risk," he continued, suggesting that the existence of the bills could help prod Treasury.

While acknowledging the obstacles to reform in the current Congress, Bill Piper, national affairs director for the Drug Policy Alliance, was more upbeat about the state of affairs on Capitol Hill. "I'm super-excited about the level of support for the Frank-Paul marijuana legalization bill," he said. "It has 15 cosponsors now, and when you consider that it is completely undoing federal marijuana prohibition, that's pretty remarkable. Three or four years ago, we couldn't even get anybody to introduce it. And I'm also pleasantly surprised by not only the number of cosponsors, but who they are. They include Reps. John Conyers (D-MI), Charlie Rangel (D-NY), and Barbara Lee (D-CA), three important members of the Congressional Black Caucus, and most recently, Rep. Raul Grijalva (D-AZ), a member of the Hispanic caucus."

In the event that the Democrats retake the House in 2013, Conyers would become chair of the House Judiciary Committee again, Piper noted. "We would have a cosponsor of a bill to end federal marijuana prohibition chairing that key committee," he said. Until then, Piper continued, "while the bill is gaining steam, it is unlikely to get a hearing in this Congress."

If the prospects are tough for marijuana reform in the current Congress, they aren't looking much better for sentencing reform, although the budget crisis could provide an opening, Piper said. "I'm not optimistic about sentencing reform, but DPA is advocating that it be added to the package of spending cuts and bills designed to reduce the deficit over the long term. If they're talking about reforming entitlements and the tax code, they should be talking about reducing unsustainable drug war spending," he argued.

The Sentencing Project's Gotsch said that while the Hill would be difficult terrain for the rest of the session, there is progress being made on the sentencing front. "The Sentencing Commission has been very good, and the Department of Justice has responded favorably to Fair Sentencing Act implementation. Justice supported retroactivity on crack, and it has also reversed course on prosecuting crack cases prior to August 2010," she said.

Even in the Congress, there are small signs of progress, she noted. "I am encouraged by things like federal good time expansion included in the Second Chance Act reauthorization. That has passed the Senate Judiciary Committee, and it even picked up one Republican vote. That's good, and that's a discussion we hadn't had before."

What Gotsch is not getting enough of is hearings, she said. "It's disappointing that there hasn't been more activity regarding hearings, but next month, the Sentencing Commission will hopefully release its mandatory minimum sentencing report, and I know the advocacy community will be pushing the Senate Judiciary Committee to hold hearings on that."

For Sterling, it is money that is going to move things in the current Congress. "According to the latest Sentencing Commission on federal drug cases, 26% of federal drug cases were marijuana cases," he noted. "With a federal drug supply reduction budget of $15.4 billion, you can argue to the Congress that if you were to pass the Frank-Paul legalization bill, you could save about $4 billion a year."

Sterling is making a similar argument to the deficit-tackling congressional Supercommittee about federal crack cocaine prosecutions. "I argue to them that if they eliminated federal crack cocaine prosecutions, which account for about 20% of federal drug cases, they could save $3.5 billion a year," he said. "Crack is made and sold locally; it shouldn't be a federal case. That should be reserved for people like Mexican cartel leaders."

But while Sterling's argument is logical, he is not sanguine about the prospects. "We could save billions of dollars a year, but I don't think something that gets translated as letting dope dealers out of prison is going to get very far. Still, it's a contemporary argument, and the money is real money. What is clear is that these expenditures are a waste; they're not keeping drugs out of the hands of the community or reducing the crime in the community, and the money could be better spent on something else."

Budget battles offer potential openings to drug reform foes as well. House Republicans are using budget bills to attempt to kill reforms they didn't like, such as opening up federal AIDS funding streams to needle exchange programs, said Hilary McQuie of the Harm Reduction Coalition.

"We have to fight this constantly in the House now," she said. "They're reinserting all these bans; they even put a syringe exchange ban rider in the foreign operations budget bill, so that's a new front, and we can't even fight it in the House. That means we have to make sure the Senate is lined up so these things can be fixed in conference committee. It feels to me like we can't make any progress in Congress right now."

McQuie said, though, that Congress isn't the only game in town. "We're looking less to Congress and more to the regulatory bodies," she said. "Obama's appointments have been pretty good, and just last week we had SAMHSA coming out with guidance to the state about applying for substance abuse block grants. This is the first big piece of money going out with explicit instructions for funding syringe exchange services. Even in this political atmosphere, there are places to fight the fight."

Where the Congress is likely to be proactive on drug policy, it's likely to be moving in the wrong direction. The ongoing panic over new synthetic drugs provides a fine opportunity for politicians to burnish their drug warrior credentials, and legislation to ban them is moving.

"I'm pessimistic about those stupid bills to outlaw Spice and bath salts," said Piper. "One bill to do that just sailed through the House Commerce Committee, and we're hoping it at least goes through Judiciary. The Republicans definitely want to move it, it went through Commerce without a hearing, and no one opposed it," he explained. "But we're working on it. Given that this is the 40th anniversary of the failed war on drugs, why add another drug to the prohibitionist model?"

"Those bills are going to pass," Sterling bluntly predicted. "There may be some quibbling over sentencing, but there's simply no organized constituency to fight it. DPA and the ACLU are concerned about civil liberties, but I don't think that's going to have much of an impact. I'd be very surprised if more than a handful of liberals vote against this."

That may not be such a bad thing, he suggested. "I'm quite willing to say that people who use these things should not be punished, but I'm not sure I want to defend the rights of people to sell unknown chemicals and call them whatever they want," he said.

Even though the evidence of harm from the new synthetics may be thin, it remains compelling, Sterling said, and few legislators are going to stand up in the face of the "urgent" problem. "Even if you argued that these drugs needed to be studied, the rejoinder is that we are facing a crisis. To challenge these bills is asking more courage of our legislators than our system tolerates."

The remainder of the current Congress is unlikely to see significant drug reform, in large part for reasons that have more to do with congressional and presidential politics than with drug policy. But that doesn't mean activists are going to roll over and play dead until 2013.

"People should continue to pressure members of Congress to get on the Frank-Paul legalization bill," urged Piper. "The more cosponsors we get, the more it helps with passing legislation at the state level, and it also helps with getting media on the issue and making it more likely that the bill will get a hearing. That's a top priority for us."

The budget issue also needs to stay highlighted, Piper said. "Whether it's Democrats or Republicans in charge, Congress is going to make cuts, and they should definitely be pressured to cut the drug war. We want the drug war on the chopping block. This is a unique historical opportunity with the recession and the focus on the budget cuts. We have to re-frame the drug war as not only failed, but too expensive to continue."

Washington, DC
United States

Drug War Issues

Criminal JusticeAsset Forfeiture, Collateral Sanctions (College Aid, Drug Taxes, Housing, Welfare), Court Rulings, Drug Courts, Due Process, Felony Disenfranchisement, Incarceration, Policing (2011 Drug War Killings, 2012 Drug War Killings, 2013 Drug War Killings, 2014 Drug War Killings, Arrests, Eradication, Informants, Interdiction, Lowest Priority Policies, Police Corruption, Police Raids, Profiling, Search and Seizure, SWAT/Paramilitarization, Task Forces, Undercover Work), Probation or Parole, Prosecution, Reentry/Rehabilitation, Sentencing (Alternatives to Incarceration, Clemency and Pardon, Crack/Powder Cocaine Disparity, Death Penalty, Decriminalization, Defelonization, Drug Free Zones, Mandatory Minimums, Rockefeller Drug Laws, Sentencing Guidelines)CultureArt, Celebrities, Counter-Culture, Music, Poetry/Literature, Television, TheaterDrug UseParaphernalia, ViolenceIntersecting IssuesCollateral Sanctions (College Aid, Drug Taxes, Housing, Welfare), Violence, Border, Budgets/Taxes/Economics, Business, Civil Rights, Driving, Economics, Education (College Aid), Employment, Environment, Families, Free Speech, Gun Policy, Human Rights, Immigration, Militarization, Money Laundering, Pregnancy, Privacy (Search and Seizure, Drug Testing), Race, Religion, Science, Sports, Women's IssuesMarijuana PolicyGateway Theory, Hemp, Marijuana -- Personal Use, Marijuana Industry, Medical MarijuanaMedicineMedical Marijuana, Science of Drugs, Under-treatment of PainPublic HealthAddiction, Addiction Treatment (Science of Drugs), Drug Education, Drug Prevention, Drug-Related AIDS/HIV or Hepatitis C, Harm Reduction (Methadone & Other Opiate Maintenance, Needle Exchange, Overdose Prevention, Safe Injection Sites)Source and Transit CountriesAndean Drug War, Coca, Hashish, Mexican Drug War, Opium ProductionSpecific DrugsAlcohol, Ayahuasca, Cocaine (Crack Cocaine), Ecstasy, Heroin, Ibogaine, ketamine, Khat, Marijuana (Gateway Theory, Marijuana -- Personal Use, Medical Marijuana, Hashish), Methamphetamine, New Synthetic Drugs (Synthetic Cannabinoids, Synthetic Stimulants), Nicotine, Prescription Opiates (Fentanyl, Oxycontin), Psychedelics (LSD, Mescaline, Peyote, Salvia Divinorum)YouthGrade School, Post-Secondary School, Raves, Secondary School